Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%) courtship, apparently after being rebuffed in reaching out to other possible buyers including Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK). Currently under discussion: a CVR that would give Genzyme upside if leukemia drug Campath proves effective against MS.